Home  |  Contact

UniProtKB/Swiss-Prot O43318: Variant p.Pro512Leu

Mitogen-activated protein kinase kinase kinase 7
Gene: MAP3K7
Chromosomal location: 6q16.1-q16.3
Variant information

Variant position:  512
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Proline (P) to Leucine (L) at position 512 (P512L, p.Pro512Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Frontometaphyseal dysplasia 2 (FMD2) [MIM:617137]: A form of frontometaphyseal dysplasia, a progressive sclerosing skeletal dysplasia affecting the long bones and skull. Characteristic features include supraorbital hyperostosis, cranial hyperostosis, undermodeling of the small bones, flared metaphyses, and digital anomalies. Extra-skeletal manifestations include hearing loss, cardiac malformations, and stenosis, particularly of the upper airway and urinary tract. FMD2 inheritance is autosomal dominant. {ECO:0000269|PubMed:27426733}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In FMD2; does not affect interaction with TAB2; does not affect homodimerization; increases autophosphorylation; increases MAPK signaling; increases NF-kappa-B signaling.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  512
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  606
The length of the canonical sequence.

Location on the sequence:   SDNSIPMAYLTLDHQLQPLA  P CPNSKESMAVFEQHCKMAQE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 606 Mitogen-activated protein kinase kinase kinase 7
Alternative sequence 509 – 518 PLAPCPNSKE -> ARTSCRTGPG. In isoform 1C and isoform 1D.
Mutagenesis 512 – 512 P -> RA. Enhances autophosphorylation; Alters MAPK signaling.


Literature citations

Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia.
Wade E.M.; Daniel P.B.; Jenkins Z.A.; McInerney-Leo A.; Leo P.; Morgan T.; Addor M.C.; Ades L.C.; Bertola D.; Bohring A.; Carter E.; Cho T.J.; Duba H.C.; Fletcher E.; Kim C.A.; Krakow D.; Morava E.; Neuhann T.; Superti-Furga A.; Veenstra-Knol I.; Wieczorek D.; Wilson L.C.; Hennekam R.C.; Sutherland-Smith A.J.; Strom T.M.; Wilkie A.O.; Brown M.A.; Duncan E.L.; Markie D.M.; Robertson S.P.;
Am. J. Hum. Genet. 99:392-406(2016)
Cited for: INVOLVEMENT IN FMD2; VARIANTS FMD2 GLN-70; GLU-100; ARG-168 AND LEU-512; CHARACTERIZATION OF VARIANTS FMD2 LEU-512 AND ARG-168; SUBUNIT; MUTAGENESIS OF PRO-512;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.